Epigenica AB, a pioneer in high-throughput epigenetic screening tools and solutions, has closed a $2.2 million round (SEK 21.5M) to fuel its growth and commercial expansion across key markets. This round was led by Voima Ventures, with participation from co-investors Navigare Ventures, Leksell Social Ventures, and current shareholder Almi Invest.
With powerful new tools, data generation from RNA, proteins and metabolites has given rise to multi-omics approaches that offer a more complete picture of biology. Epigenetics is emerging as the next essential layer in this framework, adding unique insights into how lifestyle and external factors impact how genes are turned on and off in the body, ultimately determining optimal treatment of diseases. Epigenica’s proprietary EpiFinder platform enables simultaneous analysis of multiple epigenetic markers across a large number of samples with exceptional resolution and efficiency, well suited for drug discovery and drug development.
“The field of epigenetics, which studies how our lifestyle and environment impact the way our genes work, holds transformative potential in areas like oncology, longevity and drug development,” said Stina Wallmark, Voima Ventures’ Investment Director. “Epigenica enables fast, scalable and affordable analysis of epigenetic biomarkers, helping researchers fully unlock the potential of multi-omics in the search for new diagnostics and therapies.”
“Since Epigenica’s founding, we’ve refined our technology into a broad portfolio of products serving a diverse range of epigenetics applications. We anticipate a number of significant product launches in the coming year that will enable our customers to improve and expand their research,” said Epigenica CEO Mohamad Takwa. “I’m thrilled to welcome Voima Ventures, Navigare Ventures and Leksell Social Ventures, and proud of the ongoing confidence and trust expressed by our current shareholders. This funding is a strong validation of our scientific and commercial progress.”
This funding will accelerate the development and commercialization of Epigenica’s flagship products, including the already available EpiFinder Genome and upcoming EpiFinder Global and EpiFinder cNUC kits. It will also support the build-out of the company’s service offering and data infrastructure, as well as its expansion into the U.S. market.
